Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: A report from the children's oncology group
- 31 October 2005
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 46 (3), 329-338
- https://doi.org/10.1002/pbc.20466
Abstract
Background Unresectable or metastatic disease represents the greatest obstacle to cure for children with rhabdomyosarcoma. In this study we sought to identify gene expression signatures of advanced stage and progressive disease. Procedure Using oligonucleotide gene expression analysis for a focused set of 60 genes, we analyzed the myogenic expression profiles of 89 rhabdomyosarcomas from the Intergroup Rhabdomyosarcoma Study-IV. Results While the expression profile of rhabdomyosarcomas closely paralleled gene expression profiles of normal embryonic myogenic progenitors, growth factors were most closely associated with disease progression. Specifically, we identified platelet-derived growth factor (PDGF) receptors and insulin-like growth factor as strongly correlated with decreased failure-free survival. Real-time reverse transcriptase polymerase chain reaction (RT-PCR) of an independent data set suggested that autocrine growth signaling, if present, is not regulated in a simple manner at the transcriptional level. Conclusions Increased transcriptional levels of PDGF receptors and insulin-like growth factor are associated with decreased survival in rhabdomyosarcomas. Dual blockade of these growth-factor-signaling pathways may be a valuable strategy in preclinical therapeutic studies.Keywords
This publication has 43 references indexed in Scilit:
- Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of originGenes & Development, 2004
- Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of functionGenes & Development, 2004
- Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumorsCancer Cell, 2004
- Gleevec™ for the Treatment of Chronic Myelogenous Leukemia: U.S. Food and Drug Administration Regulatory Mechanisms, Accelerated Approval, and Orphan Drug StatusThe Oncologist, 2002
- PAX3-FKHR and PAX7-FKHR Gene Fusions Are Prognostic Indicators in Alveolar Rhabdomyosarcoma: A Report From the Children’s Oncology GroupJournal of Clinical Oncology, 2002
- Pax3 Is Essential for Skeletal Myogenesis and the Expression of Six1 and Eya2Published by Elsevier BV ,2001
- Overexpression of Insulin-like Growth Factor-II in Mouse Embryonic Stem Cells Promotes Myogenic DifferentiationBiochemical and Biophysical Research Communications, 2000
- Patched Target Igf2 Is Indispensable for the Formation of Medulloblastoma and RhabdomyosarcomaPublished by Elsevier BV ,2000
- MDM2 amplification in a primary alveolar rhabdomyosarcoma displaying a t(2;13)(q35;q14)Cytogenetic and Genome Research, 1996